Pattillo R A, Komaki R, Reynolds M, Robles J
Department of Gynecology and Obstetrics, Medical College of Wisconsin, Milwaukee.
J Reprod Med. 1988 Jan;33(1):41-5.
Forty-six advanced ovarian cancer patients treated with conventional modalities with the addition of bacillus Calmette-Guérin (BCG) immunotherapy showed prolonged survival when compared to controls not given BCG. Although the data suggest enhancement of survival with the addition of BCG to conventional treatment, the fact remains that disease recurrence ultimately claims the lives of most of these patients. Nonetheless, patients are surviving longer in the face of advanced disease.
46例接受传统治疗并加用卡介苗（BCG）免疫疗法的晚期卵巢癌患者与未接受BCG治疗的对照组相比，生存期延长。尽管数据表明在传统治疗中加用BCG可提高生存率，但事实上，疾病复发最终仍夺去了这些患者中大多数人的生命。尽管如此，面对晚期疾病，患者的生存期仍在延长。
